contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-0303-2026-expres2ion-og-iss

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Assistant

Victor Skriver

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

ISS is a service company that offers services in cleaning, security, and catering. Examples of services include maintenance and supervision, floor care and window cleaning, plant decoration, and telephony services. Customers are found in most industries and on a global level, with the largest operations in the Nordic market. The company was founded in 1901 and is headquartered in Søborg, Denmark. 

Dagens aktienyheder 03/03-2026: ExpreS2ion og ISS

ExpreS2ion meddelte i g&#xe5;r at de med baggrund i lovende tidlige data i deres fase 1 vil hente op til SEK 53 mio i en fortegningsemission til at f&#xe6;rdigg&#xf8;re fase I dosis-eskaleringsstudiet (forventet medio 2026) og udvidelseskohorten (ultimo 2026) af hovedkandidaten ES2B-C001, selskabets HER2-m&#xe5;ls&#xe6;tning brystkr&#xe6;ftvaccine. 60% af udstedelsen er garanteret af ledelse, bestyrelse og garanter. L&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/expres2ion-biotech-hensigt-om-at-gennemfore-fortegningsemission-for-fuldt-ud-at-finansiere-fase-1-forsog">https://www.inderes.dk/analyst-comments/expres2ion-biotech-hensigt-om-at-gennemfore-fortegningsemission-for-fuldt-ud-at-finansiere-fase-1-forsog</a>
ISS meddelte i g&#xe5;r, efter markedets lukning, at to af selskabets ledende medarbejdere og et medarbejdervalgt bestyrelsesmedlem d. 1. marts 2026 har modtaget ISS-aktier i forbindelse med modning af aktieenheder under selskabets langsigtede incitamentsprogram (LTIP 2023) og s&#xe6;rlige incitamentsprogram (SIP 2024). Kasper Fangel (Group CEO) modtog 47.378 performance share units (PSU&apos;er), og ejer herefter 116.798,73 ISS-aktier. Mads Holm (Group CFO) modtog 3.066 restricted share units (RSU&apos;er), og ejer herefter 3.066 ISS-aktier. Det medarbejdervalgte bestyrelsesmedlem Rune Christensen modtog 2.550 PSU&apos;er, og ejer herefter 6.550 ISS-aktier. PSU&apos;erne er modnet med 96% baseret p&#xe5; indtjening pr. aktie (EPS) og det samlede aktion&#xe6;rafkast (TSR) for perioden 2023-2025, mens RSU&apos;erne er modnet 100 % baseret p&#xe5; individuelle servicem&#xe5;l.
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale. /Victor Skriver d. 03/03-2026 kl. 08:50.

HC Andersen Capital

<ul><li>ExpreS2ion planlægger at rejse op til SEK 53 mio gennem en fortegningsemission for at finansiere fase I af deres brystkræftvaccineprojekt, med 60% af udstedelsen garanteret af ledelse og bestyrelse.</li><li>ISS har tildelt aktier til ledende medarbejdere og et bestyrelsesmedlem som en del af deres langsigtede incitamentsprogrammer, med modning baseret på EPS og TSR for perioden 2023-2025.</li><li>Kasper Fangel, ISS Group CEO, modtog 47.378 PSU'er og ejer nu 116.798,73 ISS-aktier, mens Group CFO Mads Holm modtog 3.066 RSU'er og ejer nu 3.066 ISS-aktier.</li></ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Dagens aktienyheder 03/03-2026: ExpreS2ion og ISS

Summary

Stay up to date